PET/CT in benign and malignant musculoskeletal tumors and tumor-like conditions

Seminars in Musculoskeletal Radiology

Volumn 18, Issue 2, 2014, Pages 133-148

  Choi, Yun Young ^a   Kim, Ji Young ^a   Yang, Seoung Oh ^b  

^a Hanyang University Medical Center   (South Korea)

^b Asia Cancer Center (DIRAMS)   (South Korea)

Author keywords

benign; bone tumor; F 18 fluorodeoxyglucose; malignant; PET CT

Indexed keywords

ANTINEOPLASTIC AGENT; BENCE JONES PROTEIN; FLUORODEOXYGLUCOSE F 18;

ARTICLE; BENIGN TUMOR; BONE MARROW; BONE MARROW METASTASIS; BONE METASTASIS; BONE TUMOR; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER STAGING; CHONDROSARCOMA; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIFFUSION WEIGHTED IMAGING; DISEASE COURSE; EVENT FREE SURVIVAL; FASCIITIS; FIBROSARCOMA; FIBROUS DYSPLASIA; HEMANGIOMA; HUMAN; LEUKEMIA; LYMPHOMA; MALIGNANT FIBROUS HISTIOCYTOMA; MALIGNANT NEOPLASTIC DISEASE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL TUMOR; NEUROGENIC TUMOR; OSTEOCHONDROMA; OSTEOLYSIS; OSTEOSARCOMA; PLASMACYTOMA; PREDICTIVE VALUE; PRIORITY JOURNAL; RADIODIAGNOSIS; SOFT TISSUE SARCOMA; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; STEM CELL TRANSPLANTATION; TREATMENT RESPONSE; TUMOR RECURRENCE; TUMOR VOLUME; ADULT; BIOPSY; BONE NEOPLASMS; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; FEMALE; FIBROUS DYSPLASIA OF BONE; HISTIOCYTOMA, BENIGN FIBROUS; MUSCULOSKELETAL DISEASES; PARAPROTEINEMIAS; POSITRON EMISSION TOMOGRAPHY; PROCEDURES;

ADULT; BIOPSY; BONE NEOPLASMS; CHONDROSARCOMA; FASCIITIS; FEMALE; FIBROSARCOMA; FIBROUS DYSPLASIA OF BONE; FLUORODEOXYGLUCOSE F18; HISTIOCYTOMA, BENIGN FIBROUS; HUMANS; LYMPHOMA; MULTIPLE MYELOMA; MUSCULOSKELETAL DISEASES; NEOPLASM STAGING; OSTEOSARCOMA; PARAPROTEINEMIAS; PLASMACYTOMA; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84898480808     PISSN: 10897860     EISSN: 1098898X     Source Type: Journal    
DOI: 10.1055/s-0034-1371016     Document Type: Article

References (50)

1. Resnick D., Kyriakos M., Greenway G. D. Tumor and tumor-like lesions of bone: Imaging and pathology of specific lesions. In: Resnick D., Kransdorf M. J., eds. Bone and Joint Imaging. 3rd ed. Philadelphia, PA Elsevier Saunders: 2005; 1120 1198
2. Davies A. M. Primary bone tumors. In: Pope T. L., Bloem H. L., Beltran J., Morrison W. B., Wilson D. J., eds. Imaging of the Musculoskeletal System. Philadelphia, PA Saunders Elsevier: 2008; 1679 1708
3. Bielack S. S., Kempf-Bielack B., Delling G., et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol: 2002; 20 3 776 790 (Pubitemid 34111386)
4. Mialou V., Philip T., Kalifa C., et al. Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome-the French pediatric experience. Cancer: 2005; 104 5 1100 1109 (Pubitemid 41170240)
5. Peller P. J. Role of positron emission tomography/computed tomography in bone malignancies. Radiol Clin North Am: 2013; 51 5 845 864
6. Quartuccio N., Treglia G., Salsano M., et al. The role of Fluorine-18-Fluorodeoxyglucose positron emission tomography in staging and restaging of patients with osteosarcoma. Radiol Oncol: 2013; 47 2 97 102
7. Rakheja R., Makis W., Skamene S., et al. Correlating metabolic activity on 18F-FDG PET/CT with histopathologic characteristics of osseous and soft-tissue sarcomas: a retrospective review of 136 patients. AJR Am J Roentgenol: 2012; 198 6 1409 1416
8. Charest M., Hickeson M., Lisbona R., Novales-Diaz J. A., Derbekyan V., Turcotte R. E. FDG PET/CT imaging in primary osseous and soft tissue sarcomas: a retrospective review of 212 cases. Eur J Nucl Med Mol Imaging: 2009; 36 12 1944 1951
9. 18F-FDG PET/CT in the initial assessment of high-grade bone and soft tissue sarcoma. A retrospective study of 89 patients. Eur J Nucl Med Mol Imaging: 2012; 39 9 1416 1424
10. Franzius C., Daldrup-Link H. E., Sciuk J., et al. FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: comparison with spiral CT. Ann Oncol: 2001; 12 4 479 486 (Pubitemid 32472101)
11. Walter F., Czernin J., Hall T., et al. Is there a need for dedicated bone imaging in addition to 18F-FDG PET/CT imaging in pediatric sarcoma patients? J Pediatr Hematol Oncol: 2012; 34 2 131 136
12. Byun B. H., Kong C. B., Lim I., et al. Comparison of (18)F-FDG PET/CT and (99 m)Tc-MDP bone scintigraphy for detection of bone metastasis in osteosarcoma. Skeletal Radiol: 2013; 42 12 1673 1681
13. 18F-FDG PET SUVmax as an indicator of histopathologic response after neoadjuvant chemotherapy in extremity osteosarcoma. Eur J Nucl Med Mol Imaging: 2013; 40 5 728 736
14. Cheon G. J., Kim M. S., Lee J. A., et al. Prediction model of chemotherapy response in osteosarcoma by 18F-FDG PET and MRI. J Nucl Med: 2009; 50 9 1435 1440
15. Byun B. H., Kong C. B., Lim I., et al. Combination of 18F-FDG PET/CT and diffusion-weighted MR imaging as a predictor of histologic response to neoadjuvant chemotherapy: preliminary results in osteosarcoma. J Nucl Med: 2013; 54 7 1053 1059
16. Costelloe C. M., Macapinlac H. A., Madewell J. E., et al. 18F-FDG PET/CT as an indicator of progression-free and overall survival in osteosarcoma. J Nucl Med: 2009; 50 3 340 347
17. Byun B. H., Kong C. B., Park J. H., et al. Initial metabolic tumor volume measured by 18F-FDG PET/CT can predict the outcome of osteosarcoma of the extremities. J Nucl Med: 2013; 54 10 1725 1732
18. Brenner W., Conrad E. U., Eary J. F. FDG PET imaging for grading and prediction of outcome in chondrosarcoma patients. Eur J Nucl Med Mol Imaging: 2004; 31 2 189 195 (Pubitemid 38173693)
19. Aoki J., Watanabe H., Shinozaki T., Tokunaga M., Inoue T., Endo K. FDG-PET in differential diagnosis and grading of chondrosarcomas. J Comput Assist Tomogr: 1999; 23 4 603 608 (Pubitemid 29337158)
20. Arsos G., Venizelos I., Karatzas N., Koukoulidis A., Karakatsanis C. Low-grade chondrosarcomas: a difficult target for radionuclide imaging. Case report and review of the literature. Eur J Radiol: 2002; 43 1 66 72 (Pubitemid 34627000)
21. Shin D. S., Shon O. J., Han D. S., Choi J. H., Chun K. A., Cho I. H. The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors. Ann Nucl Med: 2008; 22 7 603 609
22. Ho L., Meka M., Gamble B. K., Shim J. J., Seto J. Left maxillary sinus malignant fibrous histiocytoma on FDG PET-CT. Clin Nucl Med: 2009; 34 12 967 968
23. Beal K., Allen L., Yahalom J. Primary bone lymphoma: treatment results and prognostic factors with long-term follow-up of 82 patients. Cancer: 2006; 106 12 2652 2656
24. Bosch-Barrera J., Arbea L., García-Velloso M. J., Gil-Bazo I., García-Foncillas J., Panizo C. Primary bone lymphoma of mandible and thyroid incidentaloma identified by FDG PET/CT: a case report. Cases J: 2009; 2 6384
25. Breiback F., Julian A., Laurent C., et al. Contribution of the 2-[18F]-fluoro-s-deoxy-D-glucose positron emission tomography/computed tomography to the diagnosis of primary osseous Hodgkin lymphoma. BMJ Case Rep: 2009;. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21686679. Accessed January 14, 2014
26. Lin E. C. FDG PET/CT flip flop phenomenon in treated lymphoma of bone. Clin Nucl Med: 2006; 31 12 803 805 (Pubitemid 44789563)
27. Park Y. H., Kim S., Choi S. J., et al. Clinical impact of whole-body FDG-PET for evaluation of response and therapeutic decision-making of primary lymphoma of bone. Ann Oncol: 2005; 16 8 1401 1402 (Pubitemid 41158489)
28. Kyle R. A., Rajkumar S. V. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia: 2009; 23 1 3 9
29. Bodet-Milin C., Eugène T., Bailly C., et al. FDG-PET in the evaluation of myeloma in 2012. Diagn Interv Imaging: 2012; 94 184 189
30. Durie B. G., Salmon S. E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer: 1975; 36 3 842 854
31. Durie B. G. The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system. Eur J Cancer: 2006; 42 11 1539 1543 (Pubitemid 44137426)
32. Zamagni E., Nanni C., Patriarca F., et al. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica: 2007; 92 1 50 55 (Pubitemid 46232657)
33. Bartel T. B., Haessler J., Brown T. L., et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood: 2009; 114 10 2068 2076
34. Agarwal A., Chirindel A., Shah B. A., Subramaniam R. M. Evolving role of FDG PET/CT in multiple myeloma imaging and management. AJR Am J Roentgenol: 2013; 200 4 884 890
35. Caldarella C., Isgrò M. A., Treglia I., Treglia G. Is fluorine-18-fluorodeoxyglucose positron emission tomography useful in monitoring the response to treatment in patients with multiple myeloma? Int J Hematol: 2012; 96 6 685 691
36. Nakayama M., Okizaki A., Ishitoya S., Aburano T. Hot vertebra on (18)F-FDG PET scan: a case of vertebral hemangioma. Clin Nucl Med: 2012; 37 12 1190 1193
37. Domínguez M., Rayo J., Serrano J., et al. Vertebral hemangioma: Cold vertebrae on bone scintigraphy and fluorodeoxyglucose positron emission tomography-computed tomography. Indian J Nucl Med: 2011; 26 1 49 51
38. Basu S., Nair N. Cold vertebrae on F-18 FDG PET: causes and characteristics. Clin Nucl Med: 2006; 31 8 445 450 (Pubitemid 44315491)
39. Cardona S., Schwarzbach M., Hinz U. Evaluation of F18-deoxyglucose positron emission tomography (FDG-PET) to assess the nature of neurogenic tumorous. Eur J Surg Oncol: 2003; 29 6 536 541 (Pubitemid 37009972)
40. Nose H., Otsuka H., Otomi Y., et al. Correlations between F-18 FDG PET/CT and pathological findings in soft tissue lesions. J Med Invest: 2013; 60 3-4 184 190
41. Otsuka H., Graham M. M., Kubo A., Nishitani H. FDG-PET/CT findings of sarcomatous transformation in neurofibromatosis: a case report. Ann Nucl Med: 2005; 19 1 55 58 (Pubitemid 40410289)
42. Su M. G., Tian R., Fan Q. P., et al. Recognition of fibrous dysplasia of bone mimicking skeletal metastasis on 18F-FDG PET/CT imaging. Skeletal Radiol: 2011; 40 3 295 302
43. Aras M., Ones T., Dane F., et al. False positive FDG PET/CT resulting from fibrous dysplasia of the bone in the work-up of a patient with bladder cancer: case report and review of the literature. Iran J Radiol: 2012; 10 1 41 44
44. Bonekamp D., Jacene H., Bartelt D., Aygun N. Conversion of FDG PET activity of fibrous dysplasia of the skull late in life mimicking metastatic disease. Clin Nucl Med: 2008; 33 12 909 911
45. Santiago Chinchilla A., Ramos Font C., Tello Moreno M., et al. Fibrous dysplasia of the bone. Contribution of nuclear medicine in the diagnosis of suspicion of sarcomatous degeneration. [in Spanish]. Rev Esp Med Nucl: 2010; 29 4 172 176
46. Dinauer P. A., Brixey C. J., Moncur J. T., Fanburg-Smith J. C., Murphey M. D. Pathologic and MR imaging features of benign fibrous soft-tissue tumors in adults. Radiographics: 2007; 27 1 173 187
47. Kessels L. W., Simsek S., Van Hattum A. H., Stam F., Comans E. F. Nodular fasciitis: an unexpected finding on computed tomography and positron emission tomography. Eur J Intern Med: 2004; 15 3 183 185 (Pubitemid 38900566)
48. Gotthardt M., Arens A., van der Heijden E., de Geus-Oei L. F., Oyen W. J. Nodular fasciitis on F-18 FDG PET. Clin Nucl Med: 2010; 35 10 830 831
49. Wagner L. M., Gelfand M. J., Laor T., Ryckman F. C., Al-Ghawi H., Bove K. E. A welcome surprise: nodular fasciitis presenting as soft tissue sarcoma. J Pediatr Hematol Oncol: 2011; 33 4 316 319
50. Lee S. M. Nodular fasciitis mimicking malignant tumor on 18F-FDG PET/CT. Korean J Nucl Med: 2005; 39 4 263 265